MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study

CONCLUSION: This study establishes the feasibility of online-MRIgRT for localised prostate on a 1.5 T MR-Linac with low rates of toxicity, similar to that published in the literature. However, the clinical benefits of MRIgRT over conventional radiotherapy in the setting of moderate hypofractionation is not evident. Further research will focus on the delivery of ultrahypofractionated regimens, where the potential advantages of MRIgRT for prostate cancer may become more discernible.PMID:38440792 | PMC:PMC10909700 | DOI:10.1016/j.ctro.2024.100742

Source: Clinical Prostate Cancer - March 5, 2024 Category: Cancer & Oncology Authors: Kobika Sritharan Lois Daamen Angela Pathmanathan Tine Schytte Floris Pos Ananya Choudhury Jochem R N van der Voort van Zyp Linda G W Kerkmeijer William Hall Emma Hall Helena M Verkooijen Trina Herbert Shaista Hafeez Adam Mitchell Alison C Tree Source Type: research